CR 9114
Alternative Names: CR-9114; PanFluLatest Information Update: 17 Apr 2025
At a glance
- Originator Crucell; The Scripps Research Institute
- Developer Leyden Labs
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Influenza A virus infections; Influenza B virus infections
Most Recent Events
- 08 Apr 2025 Pharmacodynamics data from a preclinical trial in Influenza A virus infections and Influenza B virus infections released by Leyden Labs
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 21 Apr 2023 Phase-I clinical trials in Influenza A virus infections (Prevention) in Netherlands (Intranasal)